PointState Capital LP grew its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 281.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,731,000 shares of the biopharmaceutical company’s stock after buying an additional 1,277,500 shares during the period. PointState Capital LP owned 1.11% of Nektar Therapeutics worth $33,841,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Nektar Therapeutics by 14.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 692 shares during the period. LS Investment Advisors LLC increased its stake in shares of Nektar Therapeutics by 8.8% during the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 535 shares during the period. Flinton Capital Management LLC increased its stake in shares of Nektar Therapeutics by 75.7% during the second quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 3,392 shares during the period. Riverhead Capital Management LLC increased its stake in shares of Nektar Therapeutics by 78.7% during the second quarter. Riverhead Capital Management LLC now owns 8,754 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 3,854 shares during the period. Finally, World Asset Management Inc increased its stake in shares of Nektar Therapeutics by 5.6% during the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 539 shares during the period. 95.08% of the stock is owned by institutional investors.

Nektar Therapeutics (NASDAQ NKTR) traded down 0.85% during trading on Friday, reaching $24.48. The company’s stock had a trading volume of 319,430 shares. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $25.02. The stock’s 50 day moving average is $21.47 and its 200 day moving average is $20.40. The company’s market cap is $3.83 billion.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.04). The firm had revenue of $34.60 million during the quarter, compared to the consensus estimate of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.36) EPS. On average, equities analysts expect that Nektar Therapeutics will post ($0.98) EPS for the current fiscal year.

In other Nektar Therapeutics news, SVP Ivan P. Gergel sold 100,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $24.14, for a total transaction of $2,414,000.00. Following the completion of the sale, the senior vice president now directly owns 84,871 shares in the company, valued at $2,048,785.94. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Gil M. Labrucherie sold 120,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $24.45, for a total transaction of $2,934,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 551,362 shares of company stock worth $12,189,658. 6.10% of the stock is owned by insiders.

A number of equities analysts have recently weighed in on the company. Jefferies Group LLC reiterated a “buy” rating and set a $23.00 target price on shares of Nektar Therapeutics in a research note on Friday, July 21st. Roth Capital set a $33.00 target price on Nektar Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. BidaskClub lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Evercore ISI assumed coverage on Nektar Therapeutics in a research note on Thursday, August 17th. They set an “in-line” rating and a $20.00 target price on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. Nektar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $26.80.

ILLEGAL ACTIVITY WARNING: “Nektar Therapeutics (NKTR) Stake Increased by PointState Capital LP” was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/nektar-therapeutics-nktr-stake-increased-by-pointstate-capital-lp/1613237.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.